REVB - Revelation Biosciences, Inc. Stock Analysis

Stock Taper

SCREENER COMPARE ANY 2 STOCKS

REVB

REVELATION BIOSCIENCES, INC.

NASDAQ

$1.05

▲ UP 1.94% (0.02)

KEY STATISTICS

Market Cap$4.10 M

52w High$11.60

52w Low$0.88

Dividend Yield—

Frequency—

P/E-0.06

Volume20.00K

Shares Out.3.91M

COMPANY

LEADERSHIP

CHIEF EXECUTIVE

James Rolke

ABOUT

SECTOR

Healthcare

WENT PUBLIC

November 17, 2020

METHOD OF GOING PUBLIC

SPAC

FULL TIME EMPLOYEES

UPCOMING EARNINGS

DateNov 5, 2026

DayThursday

Rev. Est.—

NOV

THU

SPLIT RECORD

DATE	TYPE	RATIO
2026-01-28	Reverse	1:4
2025-07-07	Reverse	1:3
2025-01-28	Reverse	1:16
2024-01-25	Reverse	1:30
2023-02-01	Reverse	1:35

PRICE

$1.05 ▲ UP 1.94% (+$0.02)

OVERLAYS

About Revelation Biosciences, Inc.

https://www.revbiosciences.com ↗

Revelation Biosciences, Inc., a San Diego-based clinical-stage biopharma founded in 2019, develops immune therapeutics and diagnostics, including GEM-AKI and GEM-CKD for kidney injury and disease.

INDUSTRY

Biotechnology

A SERVICE REVELATION BIOSCIENCES, INC. IS KNOWN FOR

Gemini

Gemini by Revelation Biosciences is an investigational intravenous formulation of PHAD® aimed at reducing inflammation-related damage and reprogramming the innate immune system for indications like AKI, CKD, and post-surgical infections.